Literature DB >> 18845092

Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis.

Robert Bissonnette1, Simon Nigen, Chantal Bolduc.   

Abstract

BACKGROUND: Genital psoriasis is difficult to treat and has a significant psychological impact on affected patients.
OBJECTIVE: To study the safety and efficacy of topical tacrolimus ointment in male patients with genital psoriasis.
METHODS: This was an open-label study in 12 male patients with genital psoriasis. Patients received topical tacrolimus 0.1% ointment twice daily for 8 weeks followed by a 4-week observational period. Efficacy was assessed by a modification of the Psoriasis Area and Severity Index (PASI) scale adapted for genital psoriasis (male genital PASI). Severity was also evaluated individually for the glans, shaft of the penis, and scrotum.
RESULTS: Male genital PASI decreased from a mean score of 15.8 at baseline to 1.2 at week 8 (p < .001). Psoriasis severity also improved significantly for the glans, shaft of the penis, and scrotum evaluated individually. Tacrolimus 0.1% ointment was very well tolerated, with only mild pruritus or burning sensation of limited duration reported.
CONCLUSIONS: Topical tacrolimus ointment appears very efficacious and well tolerated in male patients with genital psoriasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845092     DOI: 10.2310/7750.2008.07055

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  9 in total

Review 1.  Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review.

Authors:  Kim A Papp; Gurbir Dhadwal; Melinda Gooderham; Lyn Guenther; Irina Turchin; Marni Wiseman; Jensen Yeung
Journal:  Dermatol Ther       Date:  2021-09-14       Impact factor: 3.858

Review 2.  [Intertriginous psoriasis].

Authors:  C Thomas; M Matthies; B Homey; S Meller
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

3.  The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).

Authors:  Alice B Gottlieb; Brian Kirby; Caitriona Ryan; April N Naegeli; Russel Burge; Alison Potts Bleakman; Milena D Anatchkova; Gil Yosipovitch
Journal:  Dermatol Ther (Heidelb)       Date:  2017-12-04

4.  The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.

Authors:  Alice B Gottlieb; Brian Kirby; Caitriona Ryan; April N Naegeli; Russel Burge; Alison Potts Bleakman; Milena D Anatchkova; Jennifer Cather
Journal:  Dermatol Ther (Heidelb)       Date:  2017-12-04

5.  Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.

Authors:  J F Merola; P-D Ghislain; J N Dauendorffer; A Potts Bleakman; A J M Brnabic; R Burge; E Riedl
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-05       Impact factor: 6.166

Review 6.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.

Authors:  Joseph F Merola; Abrar Qureshi; M Elaine Husni
Journal:  Dermatol Ther       Date:  2018-03-06       Impact factor: 2.851

7.  Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.

Authors:  Lyn Guenther; Alison Potts Bleakman; Jamie Weisman; Yves Poulin; Lynda Spelman; Russel Burge; Janelle Erickson; Kristin Todd; Clinton C Bertram; Caitriona Ryan
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

Review 8.  Tacrolimus for the management of psoriasis: clinical utility and place in therapy.

Authors:  Nina Malecic; Helen Young
Journal:  Psoriasis (Auckl)       Date:  2016-12-07

Review 9.  Treatment of Genital Psoriasis: A Systematic Review.

Authors:  Kristen M Beck; Eric J Yang; Isabelle M Sanchez; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2018-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.